




FIG. 1B




FIG. 1A




FIG. 1C

Uniform high CAR & CXCR2 expression on engineered CAR iTs




FIG. 2

FIG. 3B

Cytolytic efficacy





FIG. 3A

Trafficking






FIG. 4A




FIG. 4B




FIG. 4C







FIG. 5



(**** P<0.0001, ***P<0.001**P<0.01)

FIG. 6



Day 45 Tumor growth inhibition




FIG. 8B




FIG. 9







FIG. 10



- TRAC: CAR/IL7RF
- TRAC: CAR/IL7RF
- CD38: hmCD16/CXCR2

FIG. 11






FIG. 13A

FIG. 13B




FIG. 14A




FIG. 14B